Jianying Zhou

13PUBLICATIONS
40CO-AUTHORS
Predictive and prognostic markersMolecular targetsEconomic theory not elsewhere classifiedHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 07, 2026
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

|May 22, 2026
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH).

|Feb 26, 2026
RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment.

Nan Jiang, Jianyong Liu, Ajay Vaghasia

|Oct 07, 2025
Case Report: A Rare EGFR 20 Insertion Variant, P772_H773insGNP Mediates Resistance to Sunvozertinib but Is Sensitive to Furmonertinib.

Yufang Wang, Jing Zheng, Jie Wang

|Aug 02, 2025
The Association Between Thromboembolic Events and ALK, ROS1, RET Rearrangements or EGFR Mutations in Patients With Advanced Lung Adenocarcinoma: A Retrospective Cohort Study.

Xiaohan Qian, Mengjiao Fu, Jing Zheng

|Aug 23, 2024
Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study.

Cuihong Cai, Qian Shen, Jingjing Shao

Pageof 3

Frequent Collaborators

2 joint publications

Jianying Zhou

2 joint publications

Wenxian Wang

2 joint publications

Hongbing Liu

2 joint publications

Liyun Miao